Navigation Links
Arrien Pharmaceuticals Appoints Dr. Philip LoGrasso to its Scientific Advisory Board for CNS/Neurodegenerative Diseases
Date:10/20/2011

ANSONIA, Conn., Oct. 20, 2011 /PRNewswire/ -- Arrien Pharmaceuticals is an early stage Drug Discovery company located in the Connecticut & Salt Lake City area announces today the appointment of Philip LoGrasso, Ph.D., to its Scientific Advisory Board. Dr. LoGrasso will work with the Arrien Pharmaceuticals team to facilitate the development of its CNS/Neurodegenerative pipeline portfolio.

"It is a great opportunity to participate in developing Arrien's promising small molecule therapeutics pipeline," said Dr. LoGrasso. "I look forward to assisting in the development of Arrien's innovative therapeutics pipeline for Parkinson's, Alzheimer's and other CNS diseases as a member of the Scientific Advisory Board."

"Dr. LoGrasso's enormous experience in developing novel therapeutics in to the clinic, as well as his strong research interests in molecular neuroscience, will be a valuable scientific addition to Arrien," stated Hariprasad, Ph.D., and Rajendra P. Appalaneni Chief Executive Officer of Arrien Pharmaceuticals. "As a leader in the field of CNS/Neurodegenerative therapeutics, Dr. LoGrasso will contribute valuable science and expertise as we move our ORS-1006 programs forward into IND enabling studies and to the clinical development."

Dr. LoGrasso is a Professor in the Molecular Therapeutics Department and Senior Director of Drug Discovery in the Translational Research Institute within The Scripps Research Institute. Prior to joining Scripps Florida, Dr. LoGrasso was a Program Officer at the NIH and had responsibility for funding a $50MM research portfolio of grants in the areas of chemical biology, medicinal chemistry, pharmacology, and postdoctoral and graduate training fellowships.

In his most recent industrial position Dr. LoGrasso was the Director of preclinical research and development at Avera Pharmaceuticals. In this role he placed two compounds into Phase II clinical development for depression and cognitive impairment.

Dr. LoGrasso was a Research Fellow at Merck Research Laboratories for nearly nine years working in the areas of inflammation and molecular neuroscience. His main research focus was on MAP-kinase signal transduction pathways and associated mechanistic enzymology, inhibitor characterization, and structure-function relationships for MAP kinases.

Dr. LoGrasso received his B.A. in chemistry from New York University in 1985, his M.S. in biochemistry from Florida State University in 1988, and his Ph.D. in pharmacology from the University of Florida in 1992. This was followed by postdoctoral training at the Sandoz Research Institute (now Novartis) working in the area of atherosclerosis and metabolic disease focusing on enzymes in the cholesterol biosynthetic pathway.

Arrien Pharmaceuticals is working for a possible licensing & alliance deals for near term funding for Phase I, II trials and to expand significantly to its value based pipeline. Arrien is seeking collaborations with companies for a number of programs particularly ORS-1006 targeting LRRK2 mediated Parkinson's disease and other CNS indications.

About Arrien Pharmaceuticals & FFDD™

Arrien Pharmaceuticals LLC is a small molecule targeted therapeutics drug discovery and development company working towards targeting cell signaling pathways - A target class in treating Neurodegenerative/CNS, Cancer, Inflammation and Metabolic diseases. Arrien proprietary Fragment-Field Drug Design (FFDD™) Technology typically involves scaffold-based design strategy; extensively implemented by utilizing structural biology data inputs and to assist Medicinal Chemistry in early phase of lead-to-drug-lead identification process. Arrien cost-competent approach assists its technology to influence target-specific leads for multiple protein targets. Moreover, Arrien technology has proven in the identification of potent and highly selective clinical stage candidates.

For further information on Arrien Pharmaceuticals, please visit the company's website www.arrienpharma.com

CONTACT:

Arrien Pharmaceuticals CEO/CSO at info@arrienpharma.com Tel. 203-331-3000 or 801-285-7427


'/>"/>
SOURCE Arrien Pharmaceuticals LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arrien Pharmaceuticals Founders closes $2.0 Million Series A Financing
2. Critical Alerts For Intel, Mosaic, Deckers, Foot Locker, and Jazz Pharmaceuticals Released By Seven Summits Research
3. Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl
4. Amylin Pharmaceuticals Reports Third Quarter Financial Results
5. CureFAKtor Pharmaceuticals to Present at 10th Annual BIO Investor Forum
6. ADVENTRX Pharmaceuticals to Present at the 10th Annual BIOInvestor Forum Conference on October 26
7. Rock Creek Pharmaceuticals Announces Expanded International Shipping Options for Anatabloc™, Physician Conferences on Anatabine Research
8. Amerigen Pharmaceuticals and Stason Pharmaceuticals Enter Into Collaboration Agreement for Development of Generic Oral Oncology Products
9. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
10. JHP Pharmaceuticals Enters Agreement to Produce Diagnostic Aid
11. Par Pharmaceutical Acquires Three Generic Products From Teva Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016  Zymo Research Corp. ... their new reference materials that help researchers obtain ... collection to analyses. The rapid growth of the ... researchers to have standard methods to improve the ... Biases inherently exist at every step of the ...
(Date:5/25/2016)... May 25, 2016  Granger Diagnostics today announced immediate ... wounds and infections. This test ensures discovery of ... viruses. The test requires only a simple swab of ... David G. Bostwick , MD, Chief Medical ... wound healing: "We are excited to make available, ...
(Date:5/25/2016)... , May 25, 2016 ... H1 2016"market research report that provides an overview ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting at a ... to wait until March 2017 for an interest rate increase, according to Rajeev Dhawan ... Business. , “The Federal Open Market Committee (FOMC) dot charts are of interest to ...
(Date:5/26/2016)... St. Louis, Missouri (PRWEB) , ... May 26, ... ... optimal cost, quality and clinical outcomes, hosted members and suppliers for its inaugural ... with a focus on their mission of elevating the operational health of America’s ...
(Date:5/26/2016)... ... 26, 2016 , ... The Woodlands at John Knox Village , Florida’s ... care for living and healing, celebrated its grand opening, today. The Woodlands at John ... provided by Empowered Staff. , “This is an incredibly fulfilling time for John Knox ...
(Date:5/26/2016)... N.J. (PRWEB) , ... May 26, 2016 , ... ... delivery technologies and development solutions for drugs, biologics, consumer health and global clinical ... sales office in Korea to support the company’s continued investment and strategic growth ...
(Date:5/26/2016)... ... , ... Memorial Day Weekend marks the unofficial start of summer and the ... make sure your family and vehicle are ready to hit the road this weekend. ... deaths and an additional 50,500 serious injuries from motor vehicle crashes during the three-day ...
Breaking Medicine News(10 mins):